Drug class
Dipeptidyl peptidase 1 (DPP1) inhibitor; anti-inflammatory small molecule
Mechanism of action
Competitively and reversibly inhibits DPP1, the enzyme that activates neutrophil serine proteases during neutrophil maturation. DPP1 inhibition reduces activity of neutrophil elastase, cathepsin G and proteinase 3, which contribute to neutrophil-mediated inflammation in bronchiectasis.
General use cases
- Treatment of non-cystic fibrosis bronchiectasis (NCFB) in adults and paediatric patients aged 12 years and older under the US FDA Brinsupri indication
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
